2023-12-20| R&D

Pioneering Vaccine Offers Hope for Affordable Cholesterol Management

by Sinead Huang
Share To

Cardiovascular disease (CVD) remains the primary cause of global mortality, claiming nearly 19 million lives in 2020. Elevated levels of low-density lipoprotein cholesterol (LDL-C) significantly contribute to atherosclerotic cardiovascular disease (ASCVD). While statins are widely prescribed, their varying effectiveness and potential adverse effects have led to the quest for alternative lipid-lowering therapies.Recently, researchers at The University of New Mexico School of Medicine have developed a PCSK9-targeting vaccine using virus-like particles, showing efficacy in reducing cholesterol levels in animal models.

Related article: FDA Extends Approval Of Regeneron’s Evkeeza For Inherited High Cholesterol

PCSK9 Inhibitors – A Breakthrough but Costly Solution

Protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, including monoclonal antibodies and siRNA-based therapies, have emerged as potent options to reduce LDL-C. FDA-approved therapies like evolocumab and alirocumab showcase efficacy but come with a hefty price tag, raising concerns about cost-effectiveness. These inhibitors, often used in conjunction with statins, are primarily employed for secondary prevention in cases where statin monotherapy falls short.

Novel VLP Vaccine – An Affordable and Efficient Alternative 

Researchers at The University of New Mexico School of Medicine have introduced a groundbreaking vaccine targeting PCSK9. Utilizing virus-like particles (VLPs), the vaccine displays specific PCSK9 peptides, inducing robust anti-PCSK9 antibody responses. Unlike traditional immunological challenges related to self-antigens, VLP-based vaccines efficiently overcome these obstacles. The cost-effective production of vaccines, coupled with their potential for fewer doses, enhances accessibility and patient compliance. The engineered VLP-based vaccine demonstrates efficacy in reducing total cholesterol levels in various animal models, offering a promising avenue for lowering LDL-C without the need for frequent statin administration.

Future Prospects and Global Impact

As the research progresses, the VLP-based vaccine targeting PCSK9 holds immense potential for revolutionizing cholesterol management. The ability to lower LDL-C levels without the frequent administration of statins could mark a significant advancement in cardiovascular care. With an estimated cost per dose under $100, the vaccine’s affordability and global applicability could address the economic constraints associated with current PCSK9 inhibitors. The ongoing efforts to move into vaccine manufacturing and clinical trials signify a ten-year timeline for potential human use, presenting an optimistic outlook for a cost-effective and efficient solution to combat high cholesterol levels globally.

© All rights reserved. Collaborate with us:
Related Post
Innovent’s PCSK-9 Antibody Meets Primary Endpoints in Two Phase 3 Studies
Verve Raises $94M in Series B, Aims to Disrupt Cardiology Market with ‘Once-and-Done’ Gene Editing Therapies
AstraZeneca Sells its Cholesterol Drug to German Pharma
Company Presentations at BIO 2024 Inspire Partnering
GV Regains Compliance with Nasdaq Minimum Bid Price Requirement
ARPA-H Fast-Tracks Biotech Startups: Funding Insights from BIO 2024 Panel
Gene Therapy Innovations and Financial Challenges for the Future of Medicine
BIO Releases DEI Survey in Partnership with Korn Ferry
Advancing Healthcare Accessibility and Sustainable Development
New CRISPR Method Enables Gene Edits in Cockroaches and All Insects
Scroll to Top